


11-26-03



Express Mail Label No.: EV 312709682 US
Date of Deposit: November 24, 2003

Attorney Docket No.: 24591-501

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Becker et al.
SERIAL NUMBER: 10/626,085 EXAMINER: Not Yet Assigned
FILING DATE: July 24, 2003 ART UNIT: Not Yet Assigned
FOR: SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AS NEUROKININ ANTAGONISTS

Mail Stop IDS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (2 pages), in duplicate;
3. Copies of Cited Reference B1-B3; C1-C30; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 24591-501. A duplicate copy of this transmittal letter is enclosed herewith.


Respectfully submitted,

Matthew Parao Reg No. 50,572

Ivor R. Elrifi, Reg. No. 39,529
Nicholas P. Triano, III, Reg. No. 36,397
Attorneys for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
Address all written correspondence to
Customer No.: 30623
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: November 24, 2003

Date of Deposit: November 24, 2003



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Becker et al.

SERIAL NUMBER: 10/626,085

EXAMINER: Not Yet Assigned

FILING DATE: July 24, 2003

ART UNIT: Not Yet Assigned

FOR: SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AS NEUROKININ ANTAGONISTS

MAIL STOP IDS

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before receipt of a first Office Action on the merits. Accordingly, no fee is believed due.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANT: Becker et al.
U.S.S.N.: 10/626,085

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 24591-501.


Respectfully submitted,

for: Matthew Pavao Reg No 50,572
Ivor R. Elrifi, Reg. No. 39,529
Nicholas P. Triano, III, Reg. No. 36,397
Attorneys for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
Address all written correspondence to
Customer No.: 30623
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: November 24, 2003

TRA 1844992v1

Please type a plus sign (+) in this box



Modified Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

| | |
|------------------------|------------------|
| Application Number | 10/626,085 |
| Filing Date | July 24, 2003 |
| First Named Inventor | Becker |
| Group Art Unit | Not Yet Assigned |
| Examiner Name | Not Yet Assigned |
| Attorney Docket Number | 24591-501 |

U.S. PATENT DOCUMENTS

| Exam Initials | Cite No. | U.S. Patent Document No. | Issue Date | Name of Patentee(s) or Applicant(s) | Class | Sub Class | Filing Date If Appropriate |
|---------------|----------|--------------------------|------------|-------------------------------------|-------|-----------|----------------------------|
| | | | | | | | |

FOREIGN PATENT DOCUMENTS

| Exam Initials | Cite No. | Foreign Patent Document Office | Number | Name of Patentee(s) or Applicant(s) | Date of Publication | Translation Yes | No |
|---------------|----------|--------------------------------|----------|-------------------------------------|---------------------|-----------------|----|
| | B1 | WO | 93/01160 | Merck Sharp & Dohme Limited | 01/21/93 | | |
| | B2 | WO | 93/01165 | Merck Sharp & Dohme Limited | 01/21/93 | | |
| | B3 | WO | 93/01169 | Merck Sharp & Dohme Limited | 01/21/93 | | |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Exam Initials | Cite No. | Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc. |
|---------------|----------|---|
| | C1 | Goadsby, et al., "Substance P Blockade with the Potent and Centrally Acting Antagonist GR205171 does not Effect Central Trigeminal Activity with Superior Sagittal Sinus Stimulation", <i>Neuroscience</i> , 1998, 86(1):337-343. |
| | C2 | Von Sprecher, et al., "Neurokinin Antagonists as Potential Therapies for Inflammation and Rheumatoid Arthritis", <i>Drugs</i> , 1998, 1(1):73-91. |
| | C3 | Hill, R.G., "Role of Receptors in Nociception", <i>The Tachykinin Receptors</i> , ed. S.H. Buck, Humana Press Inc. Totowa, NJ, 1994, 471-498. |
| | C4 | Maggi, et al., "Tachykinin Receptors and Tachykinin Receptor Antagonists", <i>J. Auton. Pharmacol.</i> , 1993, 13(1):23-93. |
| | C5 | Regoli, et al., "Receptors and Antagonists for Substance P and Related Peptides", <i>Pharmacol. Rev.</i> , 1994, 46(4): 551-599. |
| | C6 | Maggio, et al., "History of Tachykinin Peptides", <i>The Tachykinin Receptors</i> ; ed. S.H. Buck, Humana Press Inc. Totowa, NJ, 1994, 1-21. |
| | C7 | Nakanishi, S., "Mammalian Tachykinin Receptors", <i>Annu. Rev. Neurosci.</i> , 1991, 14:123-136. |
| | C8 | Bellucci, et al., "Pharmacological Profiles of the Novel Mammalian Tachykinin, Hemokinin 1", <i>Br. J. Pharmacol.</i> , 2002, 135(1):266-274. |
| | C9 | Burcher, et al., "Autoradiographic Localization of Receptors in Peripheral Tissues", <i>The Tachykinin Receptors</i> , ed. S.H. Buck, Humana Press Inc. Totowa, NJ, 1994, 125-163. |
| | C10 | Krause, et al., "Molecular Biology of Receptors", <i>The Tachykinin Receptors</i> ; ed. S.H. Buck, Humana Press Inc. Totowa, NJ, 1994, 165-218. |
| | C11 | Longmore, et al., "Neurokinin Receptors", <i>Drug News Perspect.</i> 1995, 8 (1):5-23. |
| | C12 | Kucharczyk, N., "Tachykinin Antagonists in Development", <i>Exp. Opin. Invest. Drugs</i> , 1995, 4 (4):299-311. |
| | C13 | Elliott, et al., "Neurokinin Receptor Antagonists", <i>Exp. Opin. Ther. Pat.</i> , 1997, 7 (1):43-54. |
| | C14 | Longmore, et al., "Neurokinin-Receptor Antagonists: Pharmacological Tools and Therapeutic Drugs", <i>Can. J. Physiol. Pharmacol.</i> , 1997, 75:612-621. |
| | C15 | Gerspacher, et al., "Dual Neurokinin NK ₁ /NK ₂ Receptor Antagonists", <i>Drugs Future</i> , 1999, 24(8):883-892. |
| | C16 | Kudlacz, et al., "In Vitro and In Vivo Characterization of MDL 105, 212A, a Nonpeptide NK-1/NK-2 Tachykinin Receptor Antagonists", <i>J. Pharmacol. Exp. Ther.</i> , 1996, 277(2):840-851. |
| | C17 | Ramsey, et al., "Pharmacological Characterization of ZD6021: A Novel, Orally Active Antagonist of the Tachykinin Receptors", <i>J. Pharmacol. Exp. Ther.</i> , 2001 298(1):307-315. |

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| Cite No. | Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc. |
|----------|--|
| C18 | Gerspacher, et al., "N-[(R, R)-(E)-1-(4-Chloro-benzyl)-3-(2-oxo-azepan-3-ylcarbamoyl)-allyl]-N-methyl-3,5-bis-trifluoromethyl-benzamide: An Orally Active Neukinin NK ₁ /NK ₂ Antagonist", <i>Bioorg. Med. Chem. Lett.</i> , 2000, 10: 1467-1470. |
| C19 | Shih, et al., "Design and Synthesis of the Novel and Orally Active Dual NK ₁ and NK ₂ Antagonist Sch 205528", <i>Abstract, Books of Abstracts.- Am. Chem. Soc.</i> , 2000, MEDI-129. |
| C20 | Bernstein, et al., "Discovery of Novel, Orally Active Dual NK ₁ /NK ₂ Antagonists", <i>Bioorg. Med. Chem. Lett.</i> , 2001, 11: 2769-2773. |
| C21 | Ting, et al., "Identification of a Novel 1'-[5-((3,5-dichlorobenzoyl)methylamino)-3-(3,4-dichlorophenyl)-4-methoxyimino]pentyl]-2-oxo-(1,4'-bipiperidine) as a Dual NK ₁ /NK ₂ Antagonist", <i>Bioorg. Med. Chem. Lett.</i> , 2002, 12: 2125-2128. |
| C22 | Nishi, T., "Synthetic Studies for the Novel Morpholine and Oxazolidine-Based Tachykinin Receptor Antagonists", <i>Yuki Gosei Kagaku Kyokaishi</i> , 2002, 60(7):657-667. |
| C23 | Ford-Hutchinson, et al., "Novel Therapeutic Strategies for the Treatment of Human Bronchial Asthma", <i>Drug News Perspect.</i> , 1992, 5(9):542-549. |
| C24 | Geppetti, et al., "New Aspects on the Role of Kinins in Neurogenic Inflammation", <i>Can. J. Physiol. Pharmacol.</i> , 1995, 73:843-847. |
| C25 | Advenier, et al., "The Role of Tachykinin Receptor Antagonists in the Prevention of Bronchial Hyperresponsiveness, Airway Inflammation and Cough", <i>Eur. Respir. J.</i> , 1997, 10(8):1892-1906. |
| C26 | Chapman, et al., "Tachykinins in the Lung", <i>Drug News Perspect</i> , 1998, 11(8):480-489. |
| C27 | Murai, et al., "Effects of FK224, a Novel Compound NK ₁ and NK ₂ Receptor Antagonist, on Airway Constriction and Airway Edema Induced by Neurokinins and Sensory Nerve Stimulation in Guinea Pigs", <i>J. Pharmacol. Exp. Ther.</i> , 1992, 262(1):403-408. |
| C28 | Joos, et al., "The effect of Inhaled FK224, a Tachykinin NK ₁ and NK ₂ Receptor Antagonist, on Neurokinin A-Induced Bronchoconstriction in Asthmatics", <i>Am. J. Respir. Crit. Care Med.</i> , 1996, 153(6):1781-1784. |
| C29 | Joos, et al., "Tachykinin Receptors Antagonists: Potential in Airways Diseases", <i>Curr. Opin. Pharmacol.</i> , 2001, 1(3):235-241. |
| C30 | Gerspacher, et al., "Dual Neurokinin NK ₁ /NK ₂ Antagonists: N-[(R, R)-(E)-1-arylmethyl-3-(2-oxo-azepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzoyl-N-arylmethyl-N'-methylhydrazinol]-N-[(R)-2-oxo-azepan-3-yl]propionamides", <i>Bioorg. Med. Chem. Lett.</i> , 2001, 11(23):3081-3084. |

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.